Tempest Therapeutics is a clinical-stage biotechnology company advancing a diversified portfolio of CAR-T cell therapy and small molecule product candidates. Its pipeline includes TPST-2003, an autologous CD19/BCMA dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma; amezalpat (TPST-1120), an oral PPARα antagonist that is Phase 3-ready for first-line hepatocellular carcinoma; and TPST-1495, a dual EP2/EP4 PGE2 antagonist entering Phase 2 for familial adenomatous polyposis. The company also holds allogeneic and in vivo CAR-T programs targeting CD70 and BCMA/CD19.
expected 2026-11-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001193125-26-130490 | EDGAR | 94K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-046144 | EDGAR | 74K words |
| 2024-03-19 | 2023-12-31 | 0000950170-24-033555 | EDGAR | 73K words |
| 2023-03-22 | 2022-12-31 | 0000950170-23-009237 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001628280-22-007717 | EDGAR | — |
| 2021-03-29 | 2020-12-31 | 0001544227-21-000018 | EDGAR | — |
| 2020-03-11 | 2019-12-31 | 0001544227-20-000004 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001558370-19-002660 | EDGAR | — |
| 2018-03-15 | 2017-12-31 | 0001544227-18-000002 | EDGAR | — |
| 2017-03-02 | 2016-12-31 | 0001544227-17-000002 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001193125-26-349381 | EDGAR | 27K words |
| 2025-11-05 | 2025-09-30 | 0001193125-25-265946 | EDGAR | 54K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106558 | EDGAR | 54K words |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070441 | EDGAR | 51K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125499 | EDGAR | 51K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094124 | EDGAR | 50K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-057072 | EDGAR | 48K words |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061278 | EDGAR | 51K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041429 | EDGAR | 51K words |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020579 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001544227-22-000006 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001628280-22-022788 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-17 | 0001193125-26-394492 | EDGAR | 1K words |
| 2026-09-16 | 0001193125-26-393151 | EDGAR | 1K words |
| 2026-09-15 | 0001193125-26-391903 | EDGAR | 23K words |
| 2026-08-24 | 0001193125-26-363695 | EDGAR | 1K words |
| 2026-08-18 | 0001193125-26-355550 | EDGAR | 1K words |
| 2026-08-13 | 0001193125-26-349374 | EDGAR | 3K words |
| 2026-08-13 | 0001193125-26-349334 | EDGAR | 27K words |
| 2026-07-28 | 0001193125-26-321176 | EDGAR | 1K words |
| 2026-07-22 | 0001193125-26-312391 | EDGAR | 1K words |
| 2026-03-30 | 0001193125-26-130480 | EDGAR | 2K words |
276 total filings indexed. 244 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001544227 |
| Ticker | TPST |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.tempesttx.com |
| Listed | 2021-06-28 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TPST (~200 tokens, structured JSON with cryptographic provenance)